Abstract:Background The major challenge of antitumor immunotherapy is dealing with the immunosuppressive tumor microenvironment, which involves immature myeloid cell accumulation that results in T cell dysfunction. Myeloid cell activation is induced by Toll-like receptor agonists. Additionally, granulocyte/macrophage colony stimulating factor (GM-CSF) promotes myelopoiesis and recruits myeloid cells. Here, we combined the Toll-like receptor 2 (TLR2) agonist lipoprotein and GM-CSF to assess whether this bifunctional immunotherapy has synergistic effects on myeloid cells and could be further developed as a therapeutic intervention that enhances the antitumor response. Methods We investigated the synergistic effects of biadjuvanted tumor antigen on antigen-presenting cell (APC) activation in bone marrow-derived dendritic cells. Furthermore, therapeutic efficacy was monitored in different tumor models treated via intratumoral or subcutaneous administration routes. The immune effects of the bifunctional fusion protein on myeloid cells in the tumor mass and draining lymph nodes were analyzed by flow cytometry. The induction of cytotoxic T lymphocytes was evaluated via intracellular cytokine levels, perforin/granzyme B staining and an in vivo killing assay. Results The TLR2 agonist lipoprotein combined with GM-CSF synergistically induced DC maturation, which subsequently enhanced antitumor immunity. In addition, rlipoE7m-MoGM modulated tumor-infiltrating myeloid cell populations. Vaccination with rlipoE7m-MoGM therapy increased the number of CCR7 + CD103 + cDC1s, whereas the number of suppressive tumor-associated macrophages was reduced in the tumor lesions. Consistent with this observation, proliferating antigen-specific CD8 + T cells are highly infiltrated within the tumor, and the expression of IFN-r and perforin was most pronounced within antigen-specific CD8 + T cells in mice administered rlipoE7m-MoGM therapy. This finding corresponded with observation that the combination of a TLR2 agonist and GM-CSF provides increased antitumor activity by inhibiting established tumor outgrowth and protecting against metastatic cancer compared with a TLR2 agonist alone. Importantly, tumor growth inhibition was not due to the direct effects of the TLR2 agonist or GM-CSF but was instead due to the induction of antigen-specific immunity. Conclusions The combination of a TLR2 agonist and GM-CSF has synergistic effects that inhibit tumor growth and modulate tumor-infiltrating APCs. This therapeutic approach could be applied to other tumor antigens to treat different cancers.

The potent antitumor effects of combined p16 gene and GM-CSF gene therapy through efficient induction of antitumor immunity

Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity

Study on antitumor effects of p16 and granulocyte macrophage-colony stimulating factor combined gene therapy for renal carcinoma

Therapeutic Effect of Combined Treatment with CD Suicide Gene and GM-CSF Gene on Murine Melanoma and Its Immunological Mechanism

Enhanced antitumor effects of suicide gene therapy by simultaneous transfer of GM-CSF gene in leukemia-bearing mice

Systemic genetic transfer of p21 WAF − 1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex

Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma

[Study on the Effects of Combined IL-12 and GM-CSF Gene Therapy for Murine Liver Cancer].

Enhanced Antitumor Effects of Tumor Antigen-Pulsed Dendritic Cells by Their Transfection with GM-CSF Gene.

Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity

Antitumor effect of combined therapy with adenovirus-mediated CD suicide gene and interleukin 2 gene transfer and its immunological mechanism]

Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Effects of gamma-interferon gene-modified hepatocytes on murine implanted liver carcinoma

Therapeutic effects of combined suicide gene and cytokine gene therapy on erythroleukemia-bearing mice]

A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Antitumor effect of granulocyte-macrophage colony-stimulating factor (GM-CSF)-gene encoded vaccinia melanoma oncolysate and its immunological mechanisms

Augmentation of Antitumor Effect of Adenovirus-Mediated CD Suicide Gene Therapy by Cotransfer of Interleukin 2 Gene in Melanoma-Bearing Mice.

Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment

Immune‐check blocking combination multiple cytokines shown curative potential in mice tumor model